-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Wz9yLMaVk5UCM6RyLQH/BLfoF7+KbvMPlgrh19rQ1qo7n+RlLlny1xQZ3JSDAB4N
 MXQgj8oPnwMacqHlIY3G/Q==

<SEC-DOCUMENT>0000950144-08-005351.txt : 20080707
<SEC-HEADER>0000950144-08-005351.hdr.sgml : 20080704
<ACCEPTANCE-DATETIME>20080707150730
ACCESSION NUMBER:		0000950144-08-005351
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080707
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080707
DATE AS OF CHANGE:		20080707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		08940814

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g14169e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): July&nbsp;7, 2008</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>








<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Illinois</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(State or other jurisdiction of</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(IRS Employee Identification No.)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>incorporation or organization)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(404)&nbsp;727-0971<BR>
(Issuer Telephone number)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2 below).
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4<SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> under the Exchange Act (17 CFR
240.13(e)-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!--TOC-->
<!--/TOC-->





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to
time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<!-- link1 "Item&nbsp;8.01 Other Events" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 Other Events</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;7, 2008 we issued a press release providing an update on our vaccine development
activities. A copy of the press release is attached to this Current Report.
</DIV>

<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">&nbsp;2 of 3
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: July&nbsp;7, 2008
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">&nbsp;3 of 3
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g14169exv99w1.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><IMG src="g14169g1416900.gif" alt="(GEOVAX LOGO)">

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact:</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Melanie Nimrodi, Media Contact</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">312.546.3508</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><u>mnimrodi@frbir.com</u></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">At the Company:</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Robert McNally / Jennifer Nelms</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">404.727.0971</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">FOR IMMEDIATE RELEASE
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GeoVax Reports Progress On Its AIDS Vaccine Technology</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ATLANTA, GA, July&nbsp;7, 2008 &#150; GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based, publicly traded
biopharmaceutical company specializing in the prevention and treatment of infectious diseases,
today provided an operational update on the company&#146;s progress towards entering Phase 2
preventative human clinical trial testing and plans to proceed into therapeutic human trials with
its AIDS vaccine. Five successful human trials evaluating GeoVax AIDS vaccines have previously been
reported.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Planned Phase 2 Human Clinical Trial for Prevention of AIDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#146;s Phase 2 trial, conducted by the U.S. National Institutes of Health (NIH)&nbsp;supported
HIV Vaccine Trials Network (HVTN), will involve 225 healthy volunteers from the United States and
South America, and will further evaluate the safety and immunogenicity of the GeoVax preventative
vaccine (vaccine administered prior to infection with the HIV virus). In Phase 1 trials, both
1/10<SUP style="font-size: 85%; vertical-align: text-top">th </SUP> dose and full dose of the GeoVax vaccine elicited anti-HIV T-cells, whereas the
full dose was required to elicit good frequencies of antibody to the HIV Envelope glycoprotein. The
larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the full
dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS should
they be exposed to the virus. The planned Phase 2 human clinical trial is currently scheduled to
start early this fall, subject to FDA approval.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Preclinical Data for Use of Vaccine Technology as an AIDS Therapeutic<BR>
Human Clinical Trials in Planning Stages</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax also announced summary data from a pilot study on therapeutic vaccination in simian
immunodeficiency virus (SIV)&nbsp;infected non-human primates with the SIV prototype for the GeoVax AIDS
vaccine. In this small pilot study, conducted by Dr.&nbsp;Amara at Emory University, two non-human
primates were infected with SIV. At 12&nbsp;weeks post SIV infection, conventional anti-viral drug
therapy was given to the primates to reduce the viral RNA infection levels to very low levels
creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax
AIDS vaccine was administered. Six weeks following the final vaccination, anti-viral drug treatment
was stopped and the animals were monitored to determine whether the vaccine could control the SIV
infection during the absence of the drugs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The outstanding results from the study revealed the vaccine controlling the infection in the
absence of drugs. In one primate, the reduction in viral levels over pre-drug treatment and
vaccination levels was 1000 times. In the other, the reductions in viral levels were 100 times. The
excellent control of the
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>GeoVax Labs, Inc.<BR>
Add 1</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">virus infection in the absence of drug treatment was associated with the vaccine raising the types
of CD4 and CD8 T cells that are found in the rare individuals who spontaneously control their HIV
infections.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Based on these excellent results, planning for a therapeutic trial in infected and drug treated
humans has been initiated. The intent of therapeutic vaccination is for the vaccine to &#147;control&#148;
HIV virus levels in infected individuals to very low levels thus blocking the development of AIDS.
Successful therapeutic AIDS vaccination programs with GeoVax vaccines would lead to reduction in
the use of costly anti-HIV medications and their often harmful side effects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;Harriet Robinson, GeoVax Co-founder and Senior V.P. of Research and Development, commented, &#147;I
had not anticipated the extent of vaccine control that was achieved in the already infected
non-human primates. These are highly promising results that need to be extended into infected
humans to see if the vaccine can be used to reduce the need for taking drugs. The results also
warrant more extended studies in already infected non-human primates to explore parameters that
both limit and enhance the ability for a vaccine to displace the need for drugs.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;Robert McNally, CEO and President of GeoVax Labs, Inc., emphasized, &#147;It is noteworthy to
mention that the GeoVax AIDS vaccines being tested in the preclinical therapeutic trial is the same
basic vaccine administered in the Company&#146;s human trials testing for a preventative use of the
vaccine, vaccinating people before infection to prevent the development of AIDS should they become
infected. Thus, a &#147;one for two&#148; vaccine could be a breakthrough solution for the company and the
world, saving millions of dollars in redundant development costs and years of testing time by
utilizing safety data already achieved in Phase 1 preventative human trials. More important, time
to market could be significantly reduced, saving lives much sooner than otherwise.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Further, GeoVax&#146;s management is pleased to report that the company is currently engaged in
negotiations with a NIH sponsored trial network to administer, conduct and co-sponsor GeoVax&#146;s
Therapeutic human trial program. Management expects to receive approval for undertaking formal
protocol development in the near future and will report more detailed plans accordingly.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;From an operational standpoint, we are very pleased with the overall progress of the company,&#148;
stated Dr.&nbsp;Robert McNally. &#147;Progress with ongoing preventative vaccine trials and now the potential
to address therapeutic use of the vaccine gives GeoVax an expanding role in the fight to control
AIDS.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About GeoVax Labs, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax&#146;s AIDS vaccine technology is the subject of 20 issued or filed patent
applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired
Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become
infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people
already infected with AIDS virus.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>GeoVax Labs, Inc.<BR>
Add 2</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s core AIDS vaccine technologies were developed by Dr.&nbsp;Harriet Robinson, Senior V.P. of
Research and Development, through a collaboration of colleagues at Emory University&#146;s Vaccine
Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention
(CDC)&nbsp;and GeoVax.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials
program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided
additional support to GeoVax AIDS vaccine development program with a $15&nbsp;million IPCAVD grant
awarded in late 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement: All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions on the date
of this press release and are subject to numerous risks and uncertainties which could cause actual
results to differ materially from those described in the forward-looking statements. Risks and
uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these
vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be safe for
human use, GeoVax&#146;s vaccines will effectively prevent AIDS in humans, vaccines will receive
regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to
complete vaccine development, there is development of competitive products that may be more
effective or easier to use than GeoVax&#146;s products, and other factors over which GeoVax has no
control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. Certain matters discussed in this news release are forward-looking statements
involving certain risks and uncertainties including, without limitation, risks detailed in the
Company&#146;s Securities and Exchange Commission filings and reports.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* * * * * * * * * * * * * * *
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g14169g1416900.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g14169g1416900.gif
M1TE&.#EA2P$T`.8``.7BZ=S9X:*=L<3`S<G&TH-]F,&]RV%:?#@R6FIC@]72
MW,W)U='-V*VIND(\8YJ4JXF$G5--<1L40^'>Y8V)H>CEZ[6QP?W]_7MUD3,L
M5KFUQ2(;2-G5WK&LOO7T]O#N\8:!F^[L\`8",5E2=61=@.SI[JREN/3R]1(+
M.Z6@M`@$-"TF4>KH[?/Q]'=QCIV8K5M4>"@A3;^ZR:BCM[.OOTI%:8N&H+RX
MQY:1J-K6WY*-I5%*;Y6.I7YXE$5`9?'P\STW7W5NC?OZ^TE!:./@YD]);<;#
MT/CX^7!JB9^9L8^*H=K7X7)LBE9/<W)MC%Y8>F]IB$U';)20I_GX^6YGA@H%
M-_CW^6=@@FQFATQ%:@X(.18//Y^:KD9"9]_<Y-[;X\_+UI",H\O(U,K'TT])
M<7ARD71LBZ:>M)"*I,[*UG!IAW1KC<G#T)B0IPT'-GAOCTM$;$A":/S[_/?V
M^/KY^@8"+\S%T?O[^\O(TV5C@9J/J(B#HY6/IP8",`<",?___R'Y!```````
M+`````!+`30```?_@'^"@X2%AH>(B8J+C(V.BQ0QDC`#CY:7F)F:FYR=GI^@
MH:*=%FY]?5M&HZNLK:ZOL+&RHE@B?GU-5K.[O+V^O[(>+$0!'`P+!$9&`\S-
M`\IC8@P<`1,L/Y=S$GU^(C/`X.'BX[(L'&,R2FHP70@K$BAN?O/T]?;W]:=^
M*FXH$BL(?(PPHT,#GB_8!!6PA>H$N8<0(TH<-,$$A`01'*S8H@*?QX\@0WX4
MH6)+FQ7<^E!H,;&ERY>AZ'"X\:#`DRXQ4(@4R<V/EBT2-L3(@``!$`<^DB9U
MX``(@@PK-DC8@J)C3WQ]))@0<:K*%3\H,D1)`.*!#"]W8*I="],#F`8V_TCX
MD*#BZLY;)3<@J-$D`080%!ZDH&%@#!@%.2:4^'#B"!TYA.C0\?`C1(4`"L"(
M&:"A`1<>$`I0>5)$HX01.U)JM'O+S08?9!N(F<.VMFU>$S10`&+J[CQN6S)D
M(5'@C)V$Y"K4Y4;#P08M(?N@B!!&0X7;V+-WFB!@R!;?\ZJ\!J$A@`>U.%+&
M&'2A@A@N!Q#H'+D%CH#KVO/K+W1"1Q,)OF7E@`X6Y'">;1YL,T\/BK`P1@H]
M9-"11QM$P,<$^V7(U@DR]."`%JS=PXT$3931`0,':M<`0Q*D\4@(`[S@A`];
MV&(/"@[T8`1R&O8X#A@@.(!"B/:@T@43%B@`6?^&<AR0$@E+7C(%`R]``02(
M^6B1!0@+^.BE+Q]TX("-(*%R@`X\]CC`?"K<\$E_.WQ79`P=./3EG:U\X,20
M(8F``A8<Z*((=S#X4)112OG0Q1,`M/)#$Y*LT(,0CSC!4`Q1?B)$&B3P28\(
M$E!!*9ZD>D+$$U40^:D60Q#`B!PVK'!+="ND&8H<0*1DQB,;I"1`*W<80`*6
MOVT1A)VE)OL($4PHZ%$?53B@!`N-6``$F2*IH(`K%@S91PPE-,(#5ZB$``L`
M.#A0UV\;%("?LO`BTL`*V-ZC0@P"T.$(#EO8%587`"O5%`(2N)&#*W-$<`H*
MC3*"0$]/S.)!"NK^YD?_!I7$J[$@)S`1W0866,*'C7VXX<,WBLR!``.OS&"+
M"&$P\@57?K@10"\:T%M/`1=L#"\+<*B*%Q?F/M+!K'ZL,(8C`*3(RAS]]@$$
M2XJ,T!,0OUR`AJ<B1%&TSWA.@4"]]8B0@0:7<(#EMU-$]$)/7"A20F]:/`#.
M$C5<%<<'8..9VD<J.,"W)71<D1(,3I-3@K=Q*,)%2BNT#4X+9=S2APIF]-RW
MCP:LBQ4)1&`R0-1^A#S1$Z>XP?(A5F3`C1L@C".$"[]5<?/F/;KND0@(;(L)
M[=U$('DGF\Z``PXIB*&Y(A7<\`(.`@SP]03+C8"(!O2LX+L<!+P``@A*-`!`
M_P44?-_`!1PH\3U@7APRQ0/K0P#&\(GLP)`#R^.N']+WB+!T)@_K@Q;RIPD/
MH*%?^3#)X`SQA2'P[W)1\)T#3J$%9!'"<+?`0L]F(`%L70X&!:#'KP+PL%O$
MX'^$^)L?MM``1TRA5]\BH/ZR,Y(1),Z%()*:)QB@,WR(8`5L,`0(/%4D%.C@
M#T?K@P@*8(@T*&@+THL#V=AEN28(@@6Z4P$&"I$"<FV`6H]8R`K!.,/\\*]L
M5-`$&RQ'@D,800=AB*,<Y<B#+@DB![VBQQ9JT(4-D$P"01P$!M95,N$@P'-N
MX,,?7)>5Q&&`(4/X0A:NLH$B-"$#J<K'%0:1@ZBYX?]7@EB`MU"`LD<,`$15
MH%H9M>.L?/@A8YB8P3R6:(C1"2TK2_-`"4%E`Y;)(0=*R&,?5E`T`_0F<#0P
M5Y@<\!L4I`$$+S/=(%!2,PLX@5T]4$#/2C`#W?T&!H00P'(D@*$21($;(@B"
MOBSQA5[YP(*KO$T/B"0")6CB#+.,72%<4(?H;+&+M]@`_:Y(31%0X`]"R*,(
M-FD(&#"D"0R`H0.BE`++Q8`-IE`B+`?Q`V_VH8V$2`!#5N`!X`US@8]@0(W0
M$,_\T"&/1=IB)NQ@N0,80@U"^TT1Y`###'P!$3+P5@+^<`,;!8$VAO!`WBZG
M``ST!)83W$<!#D`S-QWB!WS_Z@,3"Q'5/F1A.5I8W25TX(<KC*JEV0$#$9O9
ML&QDU`&&8$(9%!"`NMHU`!!@B/R6@P1%..ER.2@`-ZI@U4/08):]O$4=AOH'
M(JQK`Q.(P2DDH(A:=`,"A@B`K.BAQ*U*:0,D1:M^.@!3BP7AAHT((`K.*@BT
MR>LW%##!+(\X"#D8X06X?4$3>G(#&)QB`[<[Q`<LMX,_*"PK8/@#%DZA`A/\
M83D^4`1-;\'80MR@-]T8P4`;<0('9,``HMV/`:C)615(TQ)0F%496"O#030`
MMB^@QPO"B<![R"`U?<@`&0_A+02TH*A*[$$+HI:!$H1@5E%8A.6Z<(@+['8>
M;M`#_R9"`(,>M"^\^_G`#AZ(@KA=X@;0V8<,'/'>6U"`"[.TVR#RYA$-[':8
MH4.$$);3N#]L8Y@KZD;,_K#@057Q$`1`VC#WRX@E."`)&/:1!4J+BC9<X@).
MNL43,I6($JND<[?P[!]\@!4DM(`)=9".&!(QAM_T]0\/L!$"M:`*&Y]B/8D(
M83=43(@*E/!33:!R(F9P@+8F64,_$``11>``U":"`^L*G)X-864*_""'/D#J
MEB.0ADI;F@."F$%/<)`(*/3D?QZH[RU&D)#CJL#/A)"#9&\A4T(\@2%Q0&!S
M&5$"$[SKSU[Z``X0,*NL@`"EBY`E.D>`PM>:^`_S]$,5$O\L"`H8^@^+XP8*
M.&T(*7@K!I@6!`FP!<H_&*`*MY"`[P@Q!ZK^QJ:$T,$XB?`";TE`K(9HFQ7:
MB^L>A8`+.^B-&^(@@&<3X@*T4X\+!@!/]\+V#Q/PE@J:L#0B&R+9?=B`HP?Q
M`1"0KMM_8$!O(G[K(J`3"`U`3@Z^<A6&"B(`45-!"ZW@`H9D@<BVE<&MZYVL
M"C@A!K-"0`.`C8A!^LL!!PBZT`_`S%O80!`F(*0*A@`!)3C]Z4Y/`;7D<.>(
M4\$&"<!N'R)@B'-V0Y&$4,"JYQ&#`MC`!Q/ZE#[_,(>"@I3MN>H&#&[6`@+@
MX`HC%L0=`/"U/W@```"@]R)8`(+_\WI"#@$PPA@NK(D*D(<3'P!`"30'>'^'
M0@$@Z,`J`L"%#`24!.!=Q`#NO),^N&`0'2!6F7;`DCG8#W!7D&'22^;P"7A3
M1"'>NB#DX-MN9*$0(6BE%F+P`,8+PK%`:*MO5R!XQQDT%`;80#W.L(GX'G03
MN=KI'\!0,^?&(J])N,`7G'"`16]B"5S(`R81``$#\)RC.`!")J-3!.2,X0FJ
M]\@63'>"!W@^'RJ``$AV53X@`E307A]0`!V4#VXP!`8@61%'!U^P;2;D(H4`
M!M\1`U"@`4>`"%J0`<7D!EK00IE`!&,0+J#@1R,`!D:`!@[W"!-P@IL@!T,2
M!`HA`FZ`_X*P8(+G(04J@`6M4`(W``(1L`)Q0`$&D!:'T`(6``$'$`4U$(52
M.(4U$`$T("A_,`4=,@)90(54&`1?PP(/D`!%4`-%X`(I,'.%,`,1\%.'I@0D
M`(4E0@/G00,C$(5HX`126`0T@`@#T`#&=P@Q(&Z"@'8P4`()$`6+8CI+``(C
M4`1/8`%S,`,DL`,1$`0M@`%(4`)$<`!!$`81T`0"`!D`T`.*2`*N,@<0$`$U
M``-T)@C=L'8(E0)-T`4[H&)8AP81\`14H&)$H`8]D`-E``4A,`$'L`84T`0C
M,`,],P$%$(HI``(V2`A?L`\>9C4K\`?#:"YS``5O\`=&<``@@/\%.X`%7]`#
M.T`"@?0`$=`%46`#V*`!!Y`$2+`#!\`R)R"-0J`&O`8$2*`#5.`[-D`%K@4*
M`6`#(^``96`!+TASB=`%53!B=B`"35`"8!`'/0`#KE$"$]`K,;`#&?`"+B`=
M/N``-E022$026R`K;C`^UU($3N`&*R`'+><`5!`'/%`(O:("/#`JT+0!(!`#
M;N!<TJ<"&7`%6H``@@`#50`!/X"2[U4%6X!S6A`"8A-Q/E`%*B`!DO8'%D`2
M/9`"*1`#*J`&+5`2Y\%]<-`">16`*&`V$K`-&R`(.Y`'&"!]U`<%)/$.?0`'
M<I`&85$"-8`"5<`75Z`"=D,]*U!8HS#_!QQP!F\``C+0=PYY"`>@`O.U`MHR
M""?0`E&@`N;4!THI"`V@`B+09G]```OU!Q!0!U7@`2<`!"H`!F6@`A``&9])
M0B)`;88`!C`4`7-P2D!P'CB@`GEP8,_W!QOQ!\JQ`W2@FFU4`*[I`2UP2`;P
M2"C@$`HC4(0``:?PG2LT`V,@`B#519SF6W/9`R3!`G:@`D!0-%,0:`8E!UU0
M!PXP!30@`C%0`4F@`N@6%N?Q`'[@!'^@+J$7"U8P`5\0`LU7;P6@`GOPE=_(
M`B.@$\RE`/Y`?8+@,>@F""\@`D@&`W[P*S^``%KP`[FR`2H:#W1P`U7@!H)S
M""%`!2(@`J`!_Q8J"B`8$&0H8%5%H`(3``<J,&)IAF0CX`=.5J(HL&5]4%Q_
M@`0J8'*"D`'V60'-(P(;H`%IM@;Z@@5^H`%8Y`;4YZ5K@$3^^0<Z@',I@0$J
MM0%!=#1P0`<NH`(L)0-^`$Y_``!^4`0+(`(14YD/D727Q#!_(%(],`$6H`5P
MY08BT&HB!6?:Y@=L4`$;X1`$@`)*F0%:0`.<2@.FHP!-8#9=.0@>@`)U$`08
MX`<DT*DTX`5OX*>#@P4JL`8J0`:0`0,J(`8`L!'A8@1)V3I:@#)CPB"#$`)5
M(`*T90-8J@`MUX<L4",-8$P@6*!5P#=S:@,#X`=1,)F'M`2RA*<0X/\'W_!5
MC3)(>S`(09&5V0:HXP``*J`3Z%8#(F``/^!0<.4Z#C``#!``4K`/#9`#1A!J
MU2J<@B``JBH'$:`"BF0%#'`"1)`#=)!T*X`LY$,``9`"'=$!+U"KU%(-?W`M
M:V<#8.$&;F(%6U`%/V!,</4'*&9%"H,`[`9NUR<(1F":IC,$?1`%4X`$^<4`
MM:`%7R"@3:`O_R`(<%`%%B``(J`&8:)L'!!"92`(3^`'7:*B@G``?I```*`O
MZB("T<6N#]$O*(`?@E4%*%`5;:0!SA(&'S`"#)$!-W`O?^"#3Z`OM.,J-[`-
M+QH#.>`$E],-5Q`E6T$//_@'&F8+5>%DA"G_5A75!V0@"`K@!^NA;DU`*4'@
M!T=G2UDQ?,:79EL08_W"!'^@`>O"$>N17@PR`"H0!=B@HCF@-B)`%2J@!7+0
M!.8UI4M*!'[PN"Q;%QM@+H93!7T(MN2@``L07!?```TP!@"P`#'V`7^(!WQS
M`0K0`3<0`!^P`$O`G`N`'U^P`&`4)@7P`DMP`2R@`3S`!?#V!W+``";P`C3P
M+K9E`Q0P`!X@!`O``)+6`F,P!E33`MJ;I^`K"-]+-2'0OVQ`GH50`0O@.W<`
M!MT+N0]@!"P0P`&P`+3!`FEP.VG``3W#`A9P`P``!BR3`Q:8<=M2`FD08W^P
M!`/@.]=$K,0[PZU@.0,X$``#T"MFL$XOD01#%`/O1\-"W`E-$&(2$`0-.@YI
;D"HKD`)#_,2A\`%&T`%)PA8I:P'!-0B!```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
